Document Detail

Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine.
MedLine Citation:
PMID:  20118683     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was determined following a simplified 2-dose priming and the more commonly employed 3-dose priming both followed by a booster dose. METHODS: A total of 351 healthy subjects were primed with PHiD-CV at either 3 and 5 or 3, 4 and 5 months of age followed in all subjects by a booster dose at 11 to 12 months of age. Serotype-specific pneumococcal responses were measured by 22F-inhibition ELISA and opsonophagocytic assays 1 month following primary and booster vaccinations. RESULTS: Depending on the serotype, the percentages of subjects reaching the ELISA antibody threshold of 0.2 microg/mL were 92.8% to 98.0% following 2 primary doses and 96.1% to 100% following 3 primary doses except for serotype 6B (55.7% and 63.1%, respectively) and serotype 23F (69.3% and 77.6%, respectively). Opsonophagocytic activity (OPA) could be measured in 74.4% to 100% and 88.9% to 100% of the subjects after the 2-dose or 3-dose priming, respectively, except for serotype 1 (60.8% and 62.9%, respectively). In both groups, robust increases in ELISA antibodies and OPA titers were observed for all serotypes after the booster dose. Higher postprimary and postbooster ELISA antibody levels and OPA titers were observed for most serotypes following the 3+1 schedule. CONCLUSION: PHiD-CV was immunogenic in both schedules, but further effectiveness data are needed to fully understand the public health benefit to be expected from these schedules in terms of prevention against invasive and mucosal infections.
Sven Arne Silfverdal; Birthe Hogh; Marianne Riise Bergsaker; Helena Skerlikova; Patricia Lommel; Dorota Borys; Lode Schuerman
Related Documents :
8568293 - A dose-ranging study of a prototype synthetic hiv-1mn v3 branched peptide vaccine. the ...
3312103 - Vaccination against contagious caprine pleuropneumonia caused by f38.
10805623 - Vaccination of emergency department patients at high risk for influenza.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Pediatric infectious disease journal     Volume:  28     ISSN:  1532-0987     ISO Abbreviation:  Pediatr. Infect. Dis. J.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2010-02-01     Completed Date:  2010-03-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8701858     Medline TA:  Pediatr Infect Dis J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e276-82     Citation Subset:  IM    
Department of Clinical Sciences, Pediatrics, Ume? University, Ume?, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Bacterial / blood
Bacterial Proteins / immunology*
Carrier Proteins / immunology*
Enzyme-Linked Immunosorbent Assay
Haemophilus Vaccines / immunology*
Immunization, Secondary / methods*
Immunoglobulin D / immunology*
Lipoproteins / immunology*
Opsonin Proteins / blood
Pneumococcal Vaccines / immunology*
Vaccination / methods*
Vaccines, Conjugate / immunology
Reg. No./Substance:
0/10-valent pneumococcal vaccine; 0/Antibodies, Bacterial; 0/Bacterial Proteins; 0/Carrier Proteins; 0/Haemophilus Vaccines; 0/Immunoglobulin D; 0/Lipoproteins; 0/Opsonin Proteins; 0/Pneumococcal Vaccines; 0/Vaccines, Conjugate; EC protein, Haemophilus influenzae

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Kupffer cell activation by hydrogen peroxide: A new mechanism of portal pressure increase.
Next Document:  Variation of respiratory syncytial virus and the relation with meteorological factors in different w...